Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Healthcare Sector Analysis

UpdatedJan 16, 2026
DataAggregated Company Financials
Companies205
  • 7D0.6%
  • 3M13.2%
  • 1Y14.9%
  • YTD2.8%

The Healthcare industry has been flat over the last week, but Daiichi Sankyo Company has lost 6.6%. The past year has been better, since the industry has gained 15% in that time. As for the next few years, earnings are expected to grow by 11% per annum.

Sector Valuation and Performance

Has the Japanese Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 17 Jan 2026JP¥73.7tJP¥38.4tJP¥2.8t16.7x26.8x1.9x
Mon, 15 Dec 2025JP¥70.2tJP¥38.5tJP¥2.8t16x25.5x1.8x
Wed, 12 Nov 2025JP¥67.1tJP¥38.4tJP¥2.8t15.2x24.3x1.7x
Fri, 10 Oct 2025JP¥67.7tJP¥38.2tJP¥2.7t15.7x25.3x1.8x
Sun, 07 Sep 2025JP¥66.0tJP¥38.2tJP¥2.7t16x24.7x1.7x
Tue, 05 Aug 2025JP¥63.9tJP¥38.1tJP¥2.7t15.1x23.5x1.7x
Thu, 03 Jul 2025JP¥61.4tJP¥38.1tJP¥2.6t14.4x23.3x1.6x
Sat, 31 May 2025JP¥63.7tJP¥38.1tJP¥2.6t14.4x24.1x1.7x
Mon, 28 Apr 2025JP¥63.2tJP¥37.7tJP¥2.6t14.5x24.5x1.7x
Wed, 26 Mar 2025JP¥64.3tJP¥37.5tJP¥2.4t15x26.9x1.7x
Fri, 21 Feb 2025JP¥63.1tJP¥37.5tJP¥2.4t15.2x26.4x1.7x
Sun, 19 Jan 2025JP¥64.8tJP¥36.7tJP¥2.2t16.2x29x1.8x
Tue, 17 Dec 2024JP¥66.6tJP¥36.7tJP¥2.2t16.3x29.7x1.8x
Thu, 14 Nov 2024JP¥69.3tJP¥36.7tJP¥2.2t17.2x30.8x1.9x
Sat, 12 Oct 2024JP¥71.5tJP¥36.0tJP¥2.0t17.6x36x2x
Mon, 09 Sep 2024JP¥70.1tJP¥36.0tJP¥2.0t17.4x35.3x1.9x
Wed, 07 Aug 2024JP¥65.3tJP¥35.7tJP¥1.9t15.5x33.6x1.8x
Fri, 05 Jul 2024JP¥68.5tJP¥35.1tJP¥1.8t18.1x37.1x1.9x
Sun, 02 Jun 2024JP¥65.2tJP¥35.3tJP¥1.9t17.6x34.9x1.8x
Tue, 30 Apr 2024JP¥63.5tJP¥34.8tJP¥2.0t17.3x32.1x1.8x
Thu, 28 Mar 2024JP¥68.6tJP¥35.1tJP¥2.0t18.4x34.9x2x
Sat, 24 Feb 2024JP¥67.2tJP¥35.1tJP¥2.0t18.7x34.3x1.9x
Mon, 22 Jan 2024JP¥65.9tJP¥35.0tJP¥2.2t18x30.6x1.9x
Wed, 20 Dec 2023JP¥62.5tJP¥35.0tJP¥2.2t17.8x29x1.8x
Fri, 17 Nov 2023JP¥62.7tJP¥35.0tJP¥2.2t17.1x29.1x1.8x
Sun, 15 Oct 2023JP¥62.3tJP¥34.5tJP¥2.3t17.4x27.4x1.8x
Tue, 12 Sep 2023JP¥64.0tJP¥34.5tJP¥2.3t17.9x28.3x1.9x
Thu, 10 Aug 2023JP¥64.5tJP¥34.4tJP¥2.3t18.8x28.5x1.9x
Sat, 08 Jul 2023JP¥62.8tJP¥33.9tJP¥2.3t18.1x27.1x1.9x
Mon, 05 Jun 2023JP¥65.5tJP¥33.9tJP¥2.3t18.3x28.3x1.9x
Wed, 03 May 2023JP¥62.4tJP¥33.7tJP¥2.3t17.8x27.6x1.9x
Fri, 31 Mar 2023JP¥59.6tJP¥33.5tJP¥2.3t16.7x25.9x1.8x
Sun, 26 Feb 2023JP¥59.1tJP¥33.5tJP¥2.3t16.8x25.7x1.8x
Tue, 24 Jan 2023JP¥60.0tJP¥32.4tJP¥2.2t16x27.6x1.9x
Price to Earnings Ratio

27.6x


Total Market Cap: JP¥60.0tTotal Earnings: JP¥2.2tTotal Revenue: JP¥32.4tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Healthcare Sector Price to Earnings3Y Average 28.9x202420252026
Current Industry PE
  • Investors are relatively neutral on the Japanese Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 28.9x.
  • The industry is trading close to its 3-year average PS ratio of 1.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 8.1% per year over the last three years.
  • Revenues for these companies have grown 5.8% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare sector?

JP Market4.92%
Healthcare0.61%
Biotech5.38%
Healthcare Services1.12%
Medical Equipment0.93%
Pharma0.38%
Life Sciences0.27%
Healthtech-0.10%
Industry PE
  • Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 141x.
    • Analysts are expecting annual earnings growth of 18.3%, which is higher than its past year's earnings decline of 21.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 37% over the next 5 years.
  • This is better than its past earnings growth rate of 22% per year.
  • In contrast, the Healthcare Services industry is expected to see its earnings grow by 7.5% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
7741 HOYAJP¥25.33k1.3%
+JP¥113.4b		23.4%PE41x
4536 Santen PharmaceuticalJP¥1.77k5.3%
+JP¥27.0b		15.0%PE17x
4592 SanBioJP¥1.95k14.8%
+JP¥19.7b		188.7%PB309x
7777 3-D MatrixJP¥480.0036.4%
+JP¥15.4b		255.6%PE11540.4x
7730 ManiJP¥1.63k9.9%
+JP¥14.5b		10.6%PE29.3x

Latest News

7777
JP¥480.00
3-D Matrix
7D
36.4%
1Y
255.6%

3-D Matrix, Ltd.'s (TSE:7777) Price Is Right But Growth Is Lacking After Shares Rocket 46%

Jan 16
3-D Matrix, Ltd.'s (TSE:7777) Price Is Right But Growth Is Lacking After Shares Rocket 46%
7730
JP¥1,625.00
Mani
7D
9.9%
1Y
10.6%
4519
JP¥8,252.00
Chugai Pharmaceutical
7D
-2.0%
1Y
24.6%

A Look At The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Jan 14
A Look At The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
7733
JP¥2,043.00
Olympus
7D
-2.0%
1Y
-10.8%

Olympus Corporation's (TSE:7733) Price In Tune With Earnings

Jan 14
Olympus Corporation's (TSE:7733) Price In Tune With Earnings
4568
JP¥3,309.00
Daiichi Sankyo Company
7D
-6.6%
1Y
-18.9%
4506
JP¥2,750.00
Sumitomo Pharma
7D
-5.5%
1Y
400.0%

Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is Lacking

Jan 10
Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is Lacking
7741
JP¥25,325.00
HOYA
7D
1.3%
1Y
23.4%

HOYA (TSE:7741) Is Investing Its Capital With Increasing Efficiency

Jan 10
HOYA (TSE:7741) Is Investing Its Capital With Increasing Efficiency
4503
JP¥2,244.00
Astellas Pharma
7D
0.3%
1Y
50.2%
4578
JP¥9,015.00
Otsuka Holdings
7D
-0.8%
1Y
13.2%

Should You Be Adding Otsuka Holdings (TSE:4578) To Your Watchlist Today?

Jan 09
Should You Be Adding Otsuka Holdings (TSE:4578) To Your Watchlist Today?
4536
JP¥1,766.00
Santen Pharmaceutical
7D
5.3%
1Y
15.0%
4523
JP¥4,515.00
Eisai
7D
-5.3%
1Y
6.5%

4523: Future Alzheimer Subcutaneous Rollout Will Not Support Current Share Price

Analysts have maintained their price target for Eisai at ¥3,600, citing updated assumptions for revenue growth, profit margins, and future P/E that continue to support the existing valuation framework. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous autoinjector formulation of Leqembi for early Alzheimer’s disease, with similar initiation dosing applications also submitted in the U.S. and Japan (Product related announcements) Eisai and partners reported clinical and modeling data at the CTAD conference suggesting long term lecanemab treatment was associated with delayed progression from mild cognitive impairment to more advanced Alzheimer’s stages, with subcutaneous dosing showing drug exposure comparable to intravenous administration (Product related announcements) Multiple filings were completed with the U.S. FDA for Leqembi Iqlik subcutaneous initiation dosing, following earlier approval for subcutaneous maintenance dosing.
4543
JP¥2,202.00
Terumo
7D
-2.8%
1Y
-24.5%

4543: Dividend Increases And U.S. Device Adoption Will Support Balanced Outlook

Analysts have kept their price target for Terumo steady at ¥2,500, citing only minor model tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions, rather than a material change in their view of the shares. What's in the News Terumo announced a second quarter dividend for the period ending in 2026 of ¥15.00 per share, with payment scheduled for December 2, 2025.
4592
JP¥1,949.00
SanBio
7D
14.8%
1Y
188.7%
4588
JP¥1,943.00
Oncolys BioPharma
7D
27.9%
1Y
281.0%
6960
JP¥8,800.00
Fukuda Denshi
7D
4.1%
1Y
32.7%
2413
JP¥2,085.00
M3
7D
-3.3%
1Y
49.6%

M3 (TSE:2413) Is Reinvesting At Lower Rates Of Return

Dec 17
M3 (TSE:2413) Is Reinvesting At Lower Rates Of Return